Stieprox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stieprox

Quick Facts

Property Description
Active Ingredient Ciclopirox olamine
Form Medicated shampoo / Topical solution
Pharmacological Class Antifungal agent (Hydroxypyridone derivative)
General Purpose Addresses fungal proliferation on the scalp
Origin Synthetic compound

Defining Stieprox: Identity and Pharmaceutical Class

Stieprox is a commercial brand name for a prescription-only pharmaceutical product containing the single active ingredient, Ciclopirox olamine, and is primarily supplied as a medicated shampoo. The active substance is a synthetic compound that is classified as a broad-spectrum antifungal agent within the chemical family of hydroxypyridones. This classification is clinically recognized for its effectiveness against a wide range of dermatophytes, yeasts, and molds, which are often the underlying cause of persistent scalp conditions. This specific formulation is designed for non-systemic use, focusing its action exclusively on the external skin.

Form, Composition, and General Purpose

The Stieprox preparation is strictly for topical application to the external scalp, utilizing an aqueous vehicle tailored for use on hair-covered skin. Unlike topical creams formulated for smooth skin, the shampoo form of Ciclopirox olamine facilitates the treatment of the entire scalp surface. The preparation is indicated to address the fungal component in conditions often presenting with inflammation, flaking, or itchiness. The inclusion of Ciclopirox olamine as the sole active agent means the medicine is specifically focused on eliminating the causative fungi. This targeted fungicidal action is fundamental to resolving the underlying pathological state.

The Fungicidal Action of Ciclopirox Olamine

The core effect of the active ingredient, Ciclopirox olamine, is categorized as fungicidal, meaning it actively eliminates the pathogenic fungi and yeasts rather than merely inhibiting their growth. This unique, multi-faceted action is achieved by disrupting vital cellular processes, including the inhibition of metal ions, such as Fe^3+, that are critical for the organism's energy production. This targeted, eliminating action provides the definitive basis for the preparation's efficacy against fungal proliferation.

Regulatory References

  1. Ciclopirox Shampoo 1% FDA Label

What side effects are possible with Stieprox?

Possible Side Effects and Safety Information

Stieprox (ciclopirox olamine shampoo) safety profile is primarily characterized by localized reactions documented in regulatory sources under the Skin and subcutaneous tissue disorders System-Organ Class. These adverse effects are classified by frequency based on clinical trial data and post-marketing experience.


Frequency-Classified Adverse Reactions

The most frequent adverse events listed in official labeling are classified as common, typically affecting up to 1 in 10 users. These effects are generally limited to the application site and include burning sensation, pruritus (itching), and erythema (redness). Effects categorized as uncommon, such as contact dermatitis and signs of hypersensitivity (allergic reactions), have also been documented. Post-marketing experience, for which frequency cannot be reliably estimated (not known), has reported cases of hair discoloration, abnormal hair texture, and alopecia (hair loss).


Documented Safety Considerations

The medicine is formally contraindicated in individuals with a known hypersensitivity to ciclopirox olamine or any other component of the preparation. This restriction highlights the risk of serious hypersensitivity reactions documented in safety reports. For special populations, use during pregnancy is advised only if the potential benefit outweighs the potential risk, as classified under FDA Pregnancy Category B. Furthermore, the safety and efficacy of the 1% formulation are not established in pediatric patients under 16 years of age. Some local side effects, such as irritation, may be observed more frequently at the beginning of treatment, according to regulatory documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

The regulatory guidance for Stieprox (Ciclopirox olamine shampoo) details the required actions in case of overdose, reflecting the drug’s use as a topical medication with minimal systemic absorption. Because of the low absorption rate, specific systemic clinical manifestations or symptoms resulting from excessive topical application are not officially documented in the prescribing information. The primary overdose exposure scenario addressed by health authorities is the risk of accidental oral ingestion (swallowing) of the shampoo formulation.


If Stieprox is accidentally swallowed, immediate medical attention is a mandated action required by regulatory authorities. The official instruction is to contact a health care practitioner, a hospital emergency department, or a regional Poison Control Centre immediately. This help-seeking is explicitly required, even if the individual who ingested the product is showing no visible symptoms of distress.


Official regulatory summaries confirm that no specific antidote for Ciclopirox olamine overdose is known. Therefore, the required management approach is based on providing general symptomatic and supportive treatment under the direction of medical professionals. The mandated action to contact emergency services for any ingestion represents the core instruction of the product’s official overdose profile.

Therapeutic Uses of Stieprox

Quick Facts

  • Main Indication: Assists in the management of seborrheic dermatitis of the scalp.
  • Secondary Use: May be used to help control and prevent the return of dandruff.

Stieprox is a topical medication approved for the management of certain common scalp conditions. The primary therapeutic domain is the treatment of seborrheic dermatitis of the scalp in adults and adolescents over 12 years of age. This condition is characterized by redness, flaking, and itching of the scalp.

The medication works to address the symptoms associated with these dermatological conditions by acting to regulate the growth of certain organisms, such as the yeast Malassezia furfur, which are often involved in their development. By supporting the reduction of this yeast, Stieprox helps manage the symptoms of seborrheic dermatitis and control the recurrence of ordinary dandruff. It may also provide relief from related scaling and flaking. Always consult with a healthcare professional for full information regarding use and administration.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Contraindications (Who Must Not Use)

Stieprox is contraindicated and must not be used by any individual with a known hypersensitivity or allergy to the active substance, Ciclopirox olamine, or to any of the product’s non-active components. This remains the absolute exclusion criterion defined by all regulatory agencies.


Age-Group Eligibility

Official labeling defines eligibility primarily by age group:

  • Approved Use: The medication is approved for use in adults and adolescents, with the minimum age threshold generally set at 12 years (in European labeling) or 16 years (in U.S. labeling). The dosage instructions are considered suitable for older adults.
  • Pediatric Restriction: Safety and effectiveness have not been established in children below these age thresholds, meaning use in infants and young children is not formally supported by clinical data.

Conditional Use and Restrictions

  • Pregnancy and Lactation: Use during pregnancy is conditional and advised only if the potential benefit clearly justifies any potential risk. Caution must be exercised when used by nursing mothers, as it is unknown if the medication is excreted into human milk.
  • Special Populations: Clinical experience is not established for immunocompromised individuals, such as patients with HIV or long-term immunosuppressive conditions. No mandatory restrictions related to renal or hepatic impairment are documented for this topical formulation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Stieprox (ciclopirox olamine) medicated shampoo is a topical treatment, and its official interaction profile is defined by minimal systemic absorption of the active ingredient. This characteristic is the foundation for the interaction information provided in government regulatory documents.

Documented Interaction Profile

Official regulatory prescribing information consistently indicates that no drug-drug, drug-food, or drug-substance interactions have been reported or formally documented for the ciclopirox olamine shampoo formulation. This finding is directly attributed to the negligible quantity of the active substance that enters the systemic circulation following application to the scalp.

Interaction Entity Map (High-Level) Official Regulatory Documentation Statement
Contraindicated combinations None documented.
Pharmacokinetic interactions (CYP enzymes) None documented due to minimal systemic exposure.
Food, alcohol, herbal product interactions None documented.

Consequently, no specific medicinal products are listed as strictly contraindicated for co-administration due to an interaction risk. Regulatory bodies have established no mandatory timing rules for separating the administration of Stieprox from other topical or systemic products. Furthermore, information regarding interactions that modify drug exposure (e.g., AUC/Cmax alteration) or those related to drug transporter mechanisms is not included in official government labeling.

Mechanism of Action

The action of Ciclopirox olamine is defined by a dual mechanistic approach that targets both the fungal pathogen and the host’s inflammatory response, and is associated with a dual physiological effect confined to the local application site.

Fungicidal Mechanism: Energy Deprivation and Chelation

The core mechanism involves the active ingredient penetrating the fungal cell to initiate a fungicidal effect. It achieves this by chelating and removing essential polyvalent metal cations, such as Fe^3+, from the pathogen's internal machinery. The removal of these co-factors causes the functional failure of crucial iron-dependent enzymes in the mitochondrial electron transport chain (ETC), leading to significant disruption of energy ( ATP) production and resulting pathogen cell death.

Modulation of Local Inflammatory Pathways

A complementary action is exerted on the human host's skin cells through the inhibition of enzymes in the Arachidonic Acid Cascade, specifically 5-Lipoxygenase (5-LO) and Cyclooxygenase (COX). This mechanism modulates the local inflammatory response by limiting the synthesis of pro-inflammatory lipid mediators (prostaglandins and leukotrienes). This leads to a reduction in local tissue responses, resulting in a diminished profile of capillary dilation and nerve receptor activation.

Dosage and Administration Information

The administration of Stieprox (ciclopirox olamine shampoo) follows a specific usage protocol, focusing solely on the treatment of the scalp.

Administration Scope

Category Administration Guideline
Route of Administration Strictly topical application to the scalp. It is not intended for oral, ophthalmic, or intravaginal use.
Dosing Schedule A volume of approximately 1 teaspoon (5 mL) per application is generally specified. For longer hair, up to 2 teaspoons (10 mL) may be used.
Frequency Pattern The shampoo is applied twice per week for a fixed treatment course, typically with a minimum interval of 3 days observed between applications.

Procedural and Course Structure

Procedural Steps:

  • The product is applied to wet hair and massaged thoroughly into the scalp to create an abundant lather.
  • The shampoo must remain in contact with the scalp for a total duration of 3 to 5 minutes before rinsing with water.
  • The application procedure is typically repeated during the washing session.

Age-Group Rules and Duration:

  • The 1.5% formulation is indicated for use in adolescents over 12 years of age. The 1% formulation's safety for subjects younger than 16 years has not been established.
  • The standard course of treatment is designated as 4 weeks. If clinical improvement is not achieved after this period, a review of the diagnosis is usually advised.

Connection to the Overall Use Protocol

This structured protocol establishes a topical, twice-weekly frequency that requires adherence to specific volume and three-to-five-minute contact time requirements. The entire treatment is contained within a standardized 4-week course, defining the duration of use.

Recent Clinical Evidence

Research Evidence Overview for Stieprox (Ciclopirox Olamine)


Evidence for Use in Seborrheic Dermatitis of the Scalp

Ciclopirox olamine was evaluated primarily through short-term randomized controlled trials (RCTs) and systematic reviews. These studies focused on adult populations with seborrheic dermatitis, a condition characterized by fluctuating symptoms on the scalp. Researchers examined outcomes linked to inflammatory or irritative states, such as scaling, redness, and itching, typically over an initial four-week treatment period. Studies were designed to examine these outcomes versus groups receiving a non-active vehicle.


Evidence for Related Scalp Conditions

Research also explored Ciclopirox olamine for dandruff and, in some limited trials, for scalp psoriasis in adults. For dandruff, studies examined how patient-reported experiences related to flaking evolved during the study period. For psoriasis, research examined specific outcomes linked to inflammatory states, but the evidence is limited in this area, and comparative evidence is lacking.


Long-Term Evidence and Research Gaps

The core research primarily involved short-term studies. Following acute treatment, trials sometimes included intermediate observation phases (up to 12 weeks) to monitor recurrence frequency. However, long-term effects are not fully established, and there is limited information concerning sustained stability or the impact of extended use.

Research explored patient populations that included adolescents (over 12 years of age) as well as adults. Data for other groups, such as younger children, remain insufficient. Limitations include limited follow-up durations, and the fact that results apply only to the populations studied. Research provides context, but it does not determine whether an individual will respond similarly.

Key Studies & References TRANSPARENCY COMMITTEE: Clinical data on treatment and prevention of seborrhoeic dermatitis of the scalp with ciclopirox 1% shampoo (referencing the 4-week treatment and 12-week recurrence study)

Frequently Asked Questions (FAQ)

Common questions about Stieprox (FAQ)


Q: What specific conditions is Stieprox officially indicated to treat?

A: Official product information confirms that Stieprox medicated shampoo is indicated for the topical treatment of seborrheic dermatitis of the scalp. Some regulatory documents specify this treatment is approved for use in adults and adolescents over 12 years of age.

Q: How is Stieprox different from regular over-the-counter dandruff shampoos?

A: Unlike many over-the-counter options, Stieprox is a prescription-only medication. Its active ingredient, Ciclopirox olamine, is classified as an antifungal with a unique mechanism of action. This drug acts by chelating (binding to) metal ions within the fungus, which disrupts its energy production and kills the pathogenic yeast.

Q: Is Stieprox suitable for long-term or ongoing use?

A: Official documents outline a standardized treatment period, typically around 4 weeks. While the symptoms of seborrheic dermatitis may recur after treatment is stopped, the safety and effects of using the product continuously beyond this initial course are not fully established in primary regulatory studies.

Q: How long does it usually take to see improvement with Stieprox?

A: Clinical trials for this medication primarily assess significant efficacy at the 4-week endpoint. Although some individuals may notice improvement sooner, use of the product is typically maintained for the full duration of the prescribed treatment course.

Q: What can be expected if treatment with Stieprox is stopped too early?

A: Regulatory documents describe the full treatment course as the standard duration. Stopping the use of the shampoo prematurely may result in the original condition or its symptoms coming back (recurrence).

Q: What are the signs of an allergic reaction to Stieprox that require medical attention?

A: Signs of a potential serious allergic reaction that have been reported include swelling of the face, lips, or tongue, blistering, hives, or severe itching. Official information indicates that any such signs of serious hypersensitivity may require medical attention.

Q: Does Stieprox contain any steroids?

A: The active ingredient in the shampoo is Ciclopirox olamine, which is classified as an antifungal agent and a hydroxypyridone derivative. Regulatory labeling confirms that steroids are not part of the active formulation of this product.

Q: Is Stieprox safe to use during pregnancy?

A: Official product information indicates that the drug's safety for use during pregnancy has not been established through clinical trials. Therefore, its use is considered conditional, typically relying on a medical professional's assessment of potential benefit versus risk.

Q: Is Stieprox considered safe for use while breastfeeding?

A: Regulatory information indicates that caution is appropriate when this product is considered for use by nursing mothers. This is due to the fact that it is not known whether the active substance, ciclopirox, passes into human breast milk.

Q: Can people with sensitive skin generally use Stieprox?

A: During clinical studies and post-marketing surveillance, adverse effects such as mild skin irritation, redness, or a burning sensation at the application site are commonly reported. Contact dermatitis is also listed as possible.

Q: Are there any existing skin conditions that would make someone ineligible for Stieprox?

A: According to regulatory documents, the absolute exclusion criterion is a known hypersensitivity (allergy) to the active substance, Ciclopirox olamine, or any of the product's non-active components. No other specific skin diseases are listed as formal contraindications.

Q: Is Stieprox available as forms other than shampoo (like a cream or gel)?

A: While the Stieprox brand is typically supplied as a shampoo for the scalp, the active ingredient, ciclopirox, is also available under different brand names and formulations. These include creams, gels, or nail lacquers that are prescribed for other fungal infections on different parts of the body.

Q: Is there research evidence comparing Stieprox to other common antifungal shampoos?

A: Official regulatory documents describing the clinical studies generally indicate that the research was designed to compare the shampoo's efficacy against a non-active vehicle (placebo). Direct comparative trials against other common active treatments are not typically found in the primary regulatory summaries.

Q: Can Stieprox be used for fungal infections in areas other than the scalp?

A: The official route of administration is strictly for external use on the scalp only. Regulatory documents explicitly state that the shampoo is not indicated for use in any other areas of the body, including the eyes, mouth, or other skin areas.

Q: Why must Stieprox be kept out of the eyes?

A: Contact with the eyes must be avoided because the product may cause stinging and irritation of the eye tissue. If accidental contact occurs, the patient information recommends rinsing the eyes thoroughly with water.

Q: Is Stieprox considered harsh or drying on the hair or scalp?

A: Possible side effects listed in official sources include mild skin irritation, redness, or dryness at the application site. Post-marketing experience has also noted changes in hair texture, which is why some users may perceive the product as harsh or drying.

Q: Can Stieprox be used as a preventative measure after the condition has improved?

A: Official labeling defines the product's use as a treatment for the specified condition during a fixed course. The documents do not specify or contain an indication for use as a maintenance or preventative measure once the treatment course is complete.

Q: What should be done if Stieprox is accidentally swallowed?

A: If the shampoo is accidentally swallowed or used incorrectly in an excessive amount, official guidance states that a poison control center or emergency room should be contacted immediately.

Q: Does Stieprox contain sulfates or parabens?

A: Official lists of non-medicinal ingredients often confirm the inclusion of sodium laureth sulfate, which is a type of sulfate. The presence of parabens, however, is dependent on the specific formulation and may vary by region or brand version.

Q: Why might a doctor prescribe Stieprox instead of a non-prescription treatment?

A: The active ingredient has a unique dual mechanism of action that is both fungicidal (it kills the causative fungus) and modulates the local inflammatory response. This dual action, combined with its status as a prescription-only medicine, forms the basis for its prescribing rationale.

Q: What are the ingredients in Stieprox that might cause irritation?

A: Irritation or hypersensitivity reactions can be caused by the active ingredient or by other components in the formulation. Official non-medicinal ingredient lists often include common irritants such as sodium laureth sulfate and fragrance components.

Q: Is it necessary to use a gentle daily shampoo alongside Stieprox?

A: Official patient instructions and labeling indicate that you can use a mild shampoo on the days when you are not scheduled to use the medicated shampoo.

Q: Is the fragrance in Stieprox known to cause sensitivity?

A: The list of inactive ingredients confirms the presence of a fragrance. Regulatory sources note that hypersensitivity (allergic) reactions can occur due to the active ingredient or any other component, including fragrance components.

Q: Can I use Stieprox if I have color-treated hair?

A: Official warnings state that the shampoo may affect the color of your hair, and this risk is specifically noted for hair that is grey, white, or chemically damaged, which includes color-treated hair.

Q: What does a patient-rated assessment of improvement mean in clinical trials for Stieprox?

A: This refers to the structured use of defined rating scales during clinical trials. Researchers use these scales (for instance, a 0-5 score) to assess and quantify the presence and severity of key symptoms like scaling, redness, and itching, usually at the end of the treatment course.

How should Stieprox be stored and disposed of?

Official Storage and Disposal Requirements

The storage of Stieprox (Ciclopirox olamine) shampoo is defined by regulatory guidelines to ensure stability. Specific temperature requirements vary by region, but often include: Store between 4 C and 30 C or a maximum of below 30 C.

Constraint Official Requirement
Child Safety Keep out of the sight and reach of children.
Expiry Date Do not use the medicine after the expiry date printed on the package.
In-Use Stability Some labels advise to discard after the initial treatment duration or use within 8 weeks of opening.
Disposal Do not dispose of unused medicine or waste via wastewater or household waste; consult a pharmacist for safe disposal in accordance with local requirements.

These constraints mandate the temperature environment for the product and establish the critical rule that the medicine must be protected from children. Disposal must follow pharmaceutical waste rules, requiring the return of unused product to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stieprox found in:

A-Z Index: